166 results on '"Salles, Jean Pierre"'
Search Results
152. Platelet Na+-H+ exchange in juvenile diabetes mellitus.
- Author
-
Salles, Jean-Pierre, Ser, Nicole, Fauvel, Josette, Couvaras, Olga, Bouissou, François, Ghisolfi, Jacques, Barthe, Philippe, and Chap, Hugues
- Published
- 1991
- Full Text
- View/download PDF
153. WNT11, a new gene associated with early onset osteoporosis, is required for osteoblastogenesis.
- Author
-
Caetano da Silva C, Edouard T, Fradin M, Aubert-Mucca M, Ricquebourg M, Raman R, Salles JP, Charon V, Guggenbuhl P, Muller M, Cohen-Solal M, and Collet C
- Subjects
- Cell Differentiation physiology, Child, Child, Preschool, Female, Humans, Male, Middle Aged, Receptors, G-Protein-Coupled, Wnt Proteins genetics, Osteoporosis genetics, Wnt Signaling Pathway genetics
- Abstract
Monogenic early onset osteoporosis (EOOP) is a rare disease defined by low bone mineral density (BMD) that results in increased risk of fracture in children and young adults. Although several causative genes have been identified, some of the EOOP causation remains unresolved. Whole-exome sequencing revealed a de novo heterozygous loss-of-function mutation in Wnt family member 11 (WNT11) (NM_004626.2:c.677_678dup p.Leu227Glyfs*22) in a 4-year-old boy with low BMD and fractures. We identified two heterozygous WNT11 missense variants (NM_004626.2:c.217G > A p.Ala73Thr) and (NM_004626.2:c.865G > A p.Val289Met) in a 51-year-old woman and in a 61-year-old woman, respectively, both with bone fragility. U2OS cells with heterozygous WNT11 mutation (NM_004626.2:c.690_721delfs*40) generated by CRISPR-Cas9 showed reduced cell proliferation (30%) and osteoblast differentiation (80%) as compared with wild-type U2OS cells. The expression of genes in the Wnt canonical and non-canonical pathways was inhibited in these mutant cells, but recombinant WNT11 treatment rescued the expression of Wnt pathway target genes. Furthermore, the expression of RSPO2, a WNT11 target involved in bone cell differentiation, and its receptor leucine-rich repeat containing G protein-coupled receptor 5 (LGR5), was decreased in WNT11 mutant cells. Treatment with WNT5A and WNT11 recombinant proteins reversed LGR5 expression, but Wnt family member 3A (WNT3A) recombinant protein treatment had no effect on LGR5 expression in mutant cells. Moreover, treatment with recombinant RSPO2 but not WNT11 or WNT3A activated the canonical pathway in mutant cells. In conclusion, we have identified WNT11 as a new gene responsible for EOOP, with loss-of-function variant inhibiting bone formation via Wnt canonical and non-canonical pathways. WNT11 may activate Wnt signaling by inducing the RSPO2-LGR5 complex via the non-canonical Wnt pathway., (© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
154. Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR).
- Author
-
Rothenbuhler A, Esterle L, Gueorguieva I, Salles JP, Mignot B, Colle M, and Linglart A
- Subjects
- Child, Child, Preschool, Female, Humans, Male, Prospective Studies, Time Factors, Body Height, Familial Hypophosphatemic Rickets drug therapy, Genetic Diseases, X-Linked drug therapy, Human Growth Hormone therapeutic use, Puberty drug effects
- Abstract
Context: Twenty-five to 40% of patients with well-controlled X-linked hypophosphatemic rickets (XLHR) have a final height under -2 SDS. Previous studies have shown that recombinant human growth hormone (rhGH) treatment improves linear growth in short children with XLHR., Objective: We studied the effectiveness of rhGH treatment in children with XLHR in a larger cohort., Design: Monocentric, prospective, non-randomized trial., Setting: University hospital in France., Patients: 19 patients with XLHR and a mutation in the PHEX gene. Six male and 6 female Tanner stage 1 patients (age 6.1±2.4years) and 4 male and 3 female Tanner stage 2 patients (age 13.1±1years). At inclusion, height SDS was -2.35±0.8 SDS and growth velocity was -1.12±1.2 SDS., Intervention: 2years of treatment with 67mcg/kg/day of rhGH at initiation. Every three months rhGH dosage was adjusted using an IGF-1 dosing protocol., Main Outcome Measures: Comparison in change from baseline to year 2 in height and growth velocity., Results: Height SDS improved from -2.35±0.8 SDS at baseline, to -1.62±0.8 SDS (p=0.01) after one and to -1.2±1 SDS (p=0.04) after two years of rhGH treatment. There was a strong correlation (r
2 =0.6104, p<0.0001) between the age of onset of rhGH treatment and the number of cm gained over the study period. Pre-pubertal patients height SDS improved compared to baseline height SDS after one (-1.5±0.7, p<0.03) and two (-0.96±1, p<0.03) years of rhGH treatment. In pubertal patients there was no significant improvement in height SDS after one year (-1.75±1) and after two years (-1.7±0.8) of rhGH treatment., Conclusion: Two-year rhGH treatment is effective to treat short stature in XLHR children. Pre-pubertal children responded better to rhGH., Clinical Trial Registration Number: NCT02720770., (Copyright © 2017 Elsevier Ltd. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
155. Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome.
- Author
-
Burnett LC, LeDuc CA, Sulsona CR, Paull D, Rausch R, Eddiry S, Carli JF, Morabito MV, Skowronski AA, Hubner G, Zimmer M, Wang L, Day R, Levy B, Fennoy I, Dubern B, Poitou C, Clement K, Butler MG, Rosenbaum M, Salles JP, Tauber M, Driscoll DJ, Egli D, and Leibel RL
- Subjects
- Animals, Basic Helix-Loop-Helix Transcription Factors genetics, Basic Helix-Loop-Helix Transcription Factors metabolism, Diabetes Mellitus genetics, Diabetes Mellitus metabolism, Diabetes Mellitus pathology, Female, Growth Hormone-Releasing Hormone genetics, Humans, Hyperphagia genetics, Hyperphagia metabolism, Hyperphagia pathology, Hypogonadism genetics, Hypogonadism metabolism, Hypogonadism pathology, Induced Pluripotent Stem Cells metabolism, Induced Pluripotent Stem Cells pathology, Male, Mice, Knockout, Neurons pathology, Obesity genetics, Obesity metabolism, Obesity pathology, Prader-Willi Syndrome genetics, Prader-Willi Syndrome pathology, Proinsulin genetics, Protein Precursors genetics, RNA, Small Nucleolar genetics, RNA, Small Nucleolar metabolism, Growth Hormone-Releasing Hormone metabolism, Neurons metabolism, Prader-Willi Syndrome metabolism, Proinsulin metabolism, Proprotein Convertase 1 deficiency, Protein Precursors metabolism
- Abstract
Prader-Willi syndrome (PWS) is caused by a loss of paternally expressed genes in an imprinted region of chromosome 15q. Among the canonical PWS phenotypes are hyperphagic obesity, central hypogonadism, and low growth hormone (GH). Rare microdeletions in PWS patients define a 91-kb minimum critical deletion region encompassing 3 genes, including the noncoding RNA gene SNORD116. Here, we found that protein and transcript levels of nescient helix loop helix 2 (NHLH2) and the prohormone convertase PC1 (encoded by PCSK1) were reduced in PWS patient induced pluripotent stem cell-derived (iPSC-derived) neurons. Moreover, Nhlh2 and Pcsk1 expression were reduced in hypothalami of fasted Snord116 paternal knockout (Snord116p-/m+) mice. Hypothalamic Agrp and Npy remained elevated following refeeding in association with relative hyperphagia in Snord116p-/m+ mice. Nhlh2-deficient mice display growth deficiencies as adolescents and hypogonadism, hyperphagia, and obesity as adults. Nhlh2 has also been shown to promote Pcsk1 expression. Humans and mice deficient in PC1 display hyperphagic obesity, hypogonadism, decreased GH, and hypoinsulinemic diabetes due to impaired prohormone processing. Here, we found that Snord116p-/m+ mice displayed in vivo functional defects in prohormone processing of proinsulin, pro-GH-releasing hormone, and proghrelin in association with reductions in islet, hypothalamic, and stomach PC1 content. Our findings suggest that the major neuroendocrine features of PWS are due to PC1 deficiency., Competing Interests: The authors have declared that no conflict of interest exists.
- Published
- 2017
- Full Text
- View/download PDF
156. Bone metabolism during pregnancy.
- Author
-
Salles JP
- Subjects
- Animals, Female, Humans, Infant, Newborn, Osteoporosis diagnosis, Osteoporosis therapy, Parathyroid Hormone physiology, Pregnancy physiology, Receptors, Calcium-Sensing physiology, Bone Remodeling physiology, Bone and Bones metabolism, Pregnancy metabolism
- Abstract
During pregnancy, mineral concentrations, of calcium and phosphorus in particular, are maintained at a high level in fetal blood so that the developing skeleton may accrete adequate mineral content. The placenta actively transports minerals for this purpose. Maternal intestinal absorption increases in order to meet the fetal demand for calcium, which is only partly dependent on calcitriol. Mineral regulation is essentially dependent on parathyroid hormone (PTH) and PTH-related protein (PTHrP). The calcium-sensing receptor (CaSR) regulates PTH and PTHrP production. If calcium intake is insufficient, the maternal skeleton will undergo resorption due to PTHrP. After birth, a switch from fetal to neonatal homeostasis occurs through increase in PTH and calcitriol, and developmental adaptation of the kidneys and intestines with bone turnover contributing additional mineral to the circulation. Calcium absorption becomes progressively active and dependent on calcitriol. The postnatal skeleton can transiently present with osteoposis but adequate mineral diet usually allows full restoration. Cases of primary osteoporosis must be identified. Loss of trabecular mineral content occurs during lactation in order to provide calcium to the newborn. This programmed bone loss is dependent on a "brain-breast-bone" circuit. The physiological bone resorption during reproduction does not normally cause fractures or persistent osteoporosis. Women who experience fracture are likely to have other causes of bone loss., (Copyright © 2016. Published by Elsevier Masson SAS.)
- Published
- 2016
- Full Text
- View/download PDF
157. Clinical Forms and Animal Models of Hypophosphatasia.
- Author
-
Salles JP
- Subjects
- Adult, Animals, Child, Humans, Hypophosphatasia diagnosis, Hypophosphatasia genetics, Infant, Mice, Knockout, Pain diagnosis, Pain etiology, Pain pathology, Disease Models, Animal, Hypophosphatasia classification, Hypophosphatasia pathology, Mice
- Abstract
Hypophosphatasia (HPP) is due to mutations of the tissue non-specific alkaline phosphatase (TNAP) gene expressed in the liver, kidney, and bone. TNAP substrates include inorganic pyrophosphate cleaved into inorganic phosphate (Pi) in bone, pyridoxal-5'-phosphate (PLP), the circulating form of vitamin B6, and phosphoethanolamine (PEA). As an autosomal recessive or dominant disease, HPP results in a range of clinical forms. Its hallmarks are low alkaline phosphatase (AP) and elevated PLP and PEA levels. Perinatal HPP may cause early death with respiratory insufficiency and hypomineralization resulting in deformed limbs and sometimes near-absence of bones and skull. Infantile HPP is diagnosed before 6 months of life. Respiratory failure, rib fractures and seizures due to vitamin B6 deficiency in the brain indicate poor prognosis. Craniosynostosis is frequent. Unlike in other forms of rickets, calcium and phosphorus are not decreased, resulting in hypercalciuria and nephrocalcinosis. Hypercalcemic crisis may occur. Failure to thrive and growth retardation are concerns. In infantile and adult forms of HPP, non-traumatic fractures may be the prominent manifestation, with otherwise unexplained chronic pain. Progressive myopathy has been described. Dental manifestations with early loss of teeth are usual in HPP and in a specific form, odontohypophosphatasia. HPP has been studied in knock-out mice models which mimic its severe form. Animal models have made a major contribution to the development of an original enzyme therapy for human infantile HPP, which is however essentially targeted at mineralized tissues. Better knowledge of its extraskeletal manifestations, including pain and neurological symptoms, is therefore required.
- Published
- 2015
- Full Text
- View/download PDF
158. LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity.
- Author
-
Tajan M, Batut A, Cadoudal T, Deleruyelle S, Le Gonidec S, Saint Laurent C, Vomscheid M, Wanecq E, Tréguer K, De Rocca Serra-Nédélec A, Vinel C, Marques MA, Pozzo J, Kunduzova O, Salles JP, Tauber M, Raynal P, Cavé H, Edouard T, Valet P, and Yart A
- Subjects
- Adipocytes cytology, Adipose Tissue metabolism, Adiposity, Animals, Body Composition, Cell Differentiation, Disease Models, Animal, Energy Metabolism, Insulin metabolism, Lentivirus metabolism, Lipolysis, MAP Kinase Kinase Kinase 1 antagonists & inhibitors, Male, Mice, Mice, Transgenic, Mutation, Phenotype, Recombination, Genetic, Diet, LEOPARD Syndrome genetics, Obesity prevention & control, Protein Tyrosine Phosphatase, Non-Receptor Type 11 genetics, Thinness genetics
- Abstract
LEOPARD syndrome (multiple Lentigines, Electrocardiographic conduction abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormal genitalia, Retardation of growth, sensorineural Deafness; LS), also called Noonan syndrome with multiple lentigines (NSML), is a rare autosomal dominant disorder associating various developmental defects, notably cardiopathies, dysmorphism, and short stature. It is mainly caused by mutations of the PTPN11 gene that catalytically inactivate the tyrosine phosphatase SHP2 (Src-homology 2 domain-containing phosphatase 2). Besides its pleiotropic roles during development, SHP2 plays key functions in energetic metabolism regulation. However, the metabolic outcomes of LS mutations have never been examined. Therefore, we performed an extensive metabolic exploration of an original LS mouse model, expressing the T468M mutation of SHP2, frequently borne by LS patients. Our results reveal that, besides expected symptoms, LS animals display a strong reduction of adiposity and resistance to diet-induced obesity, associated with overall better metabolic profile. We provide evidence that LS mutant expression impairs adipogenesis, triggers energy expenditure, and enhances insulin signaling, three features that can contribute to the lean phenotype of LS mice. Interestingly, chronic treatment of LS mice with low doses of MEK inhibitor, but not rapamycin, resulted in weight and adiposity gains. Importantly, preliminary data in a French cohort of LS patients suggests that most of them have lower-than-average body mass index, associated, for tested patients, with reduced adiposity. Altogether, these findings unravel previously unidentified characteristics for LS, which could represent a metabolic benefit for patients, but may also participate to the development or worsening of some traits of the disease. Beyond LS, they also highlight a protective role of SHP2 global LS-mimicking modulation toward the development of obesity and associated disorders.
- Published
- 2014
- Full Text
- View/download PDF
159. Prader-Willi syndrome as a model of human hyperphagia.
- Author
-
Tauber M, Diene G, Mimoun E, Çabal-Berthoumieu S, Mantoulan C, Molinas C, Muscatelli F, and Salles JP
- Subjects
- Feeding Behavior, Humans, Brain metabolism, Dopamine metabolism, Ghrelin metabolism, Hyperphagia metabolism, Prader-Willi Syndrome metabolism
- Abstract
Prader-Willi syndrome (PWS), first described in 1956, is considered as a paradigm of a neurodevelopmental disorder with severe and early obesity with hyperphagia and impaired satiety. The improved knowledge in the natural history and recent data on genetics offer new perspectives for understanding the metabolic and endocrine dysfunctions and possibly for treatment. Natural history of the disease has been described due to the early diagnosis performed in the first months of life and various nutritional phases have been described. In addition, there is clear evidence that the abnormal feeding behavior is included in the behavioral problems. Brain imaging studies have shown that some brain regions may be important in PWS. The role of SNORD116 gene cluster is detailed and its links with circadian rhythm and brain and hypothalamus development. Pathophysiology of the abnormal ghrelin levels and of OT dysfunction is documented. While no effect on appetite and weight regulation has been reported with ghrelin antagonists, OT has been shown to improve some of the behavioral problems in adults. We discuss our hypothesis of an abnormal ghrelin/OT/dopamine pathway which may explain the switch of nutritional phases and behavior. These new aspects offer an opportunity for therapeutic use and possible early intervention., (© 2014 S. Karger AG, Basel.)
- Published
- 2014
- Full Text
- View/download PDF
160. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
- Author
-
De Rocca Serra-Nédélec A, Edouard T, Tréguer K, Tajan M, Araki T, Dance M, Mus M, Montagner A, Tauber M, Salles JP, Valet P, Neel BG, Raynal P, and Yart A
- Subjects
- Adaptor Proteins, Signal Transducing, Animals, Animals, Newborn, Binding Sites, Biometry, Enzyme Activation drug effects, Insulin-Like Growth Factor I biosynthesis, Janus Kinase 2 metabolism, Mice, Mitogen-Activated Protein Kinase Kinases antagonists & inhibitors, Mitogen-Activated Protein Kinase Kinases metabolism, Noonan Syndrome blood, Noonan Syndrome genetics, Phosphatidylinositol 3-Kinases metabolism, Phosphoproteins metabolism, Phosphorylation drug effects, Protein Tyrosine Phosphatase, Non-Receptor Type 11 metabolism, Proto-Oncogene Proteins c-akt metabolism, Rats, STAT5 Transcription Factor metabolism, ras Proteins metabolism, Extracellular Signal-Regulated MAP Kinases metabolism, Growth Hormone pharmacology, Insulin-Like Growth Factor I metabolism, Mutation genetics, Noonan Syndrome enzymology, Protein Tyrosine Phosphatase, Non-Receptor Type 11 genetics
- Abstract
Noonan syndrome (NS), a genetic disease caused in half of cases by activating mutations of the tyrosine phosphatase SHP2 (PTPN11), is characterized by congenital cardiopathies, facial dysmorphic features, and short stature. How mutated SHP2 induces growth retardation remains poorly understood. We report here that early postnatal growth delay is associated with low levels of insulin-like growth factor 1 (IGF-1) in a mouse model of NS expressing the D61G mutant of SHP2. Conversely, inhibition of SHP2 expression in growth hormone (GH)-responsive cell lines results in increased IGF-1 release upon GH stimulation. SHP2-deficient cells display decreased ERK1/2 phosphorylation and rat sarcoma (RAS) activation in response to GH, whereas expression of NS-associated SHP2 mutants results in ERK1/2 hyperactivation in vitro and in vivo. RAS/ERK1/2 inhibition in SHP2-deficient cells correlates with impaired dephosphorylation of the adaptor Grb2-associated binder-1 (GAB1) on its RAS GTPase-activating protein (RASGAP) binding sites and is rescued by interfering with RASGAP recruitment or function. We demonstrate that inhibition of ERK1/2 activation results in an increase of IGF-1 levels in vitro and in vivo, which is associated with significant growth improvement in NS mice. In conclusion, NS-causing SHP2 mutants inhibit GH-induced IGF-1 release through RAS/ERK1/2 hyperactivation, a mechanism that could contribute to growth retardation. This finding suggests that, in addition to its previously shown beneficial effect on NS-linked cardiac and craniofacial defects, RAS/ERK1/2 modulation could also alleviate the short stature phenotype in NS caused by PTPN11 mutations.
- Published
- 2012
- Full Text
- View/download PDF
161. The role of cell surface markers and enamel matrix derivatives on human periodontal ligament mesenchymal progenitor responses in vitro.
- Author
-
Kémoun P, Gronthos S, Snead ML, Rue J, Courtois B, Vaysse F, Salles JP, and Brunel G
- Subjects
- Amelogenin isolation & purification, Animals, Bone Morphogenetic Proteins isolation & purification, Cell Differentiation, Cell Proliferation, Cells, Cultured, Dental Enamel chemistry, Humans, Mesenchymal Stem Cells metabolism, Swine, Wound Healing, Amelogenin metabolism, Bone Morphogenetic Proteins metabolism, Mesenchymal Stem Cells cytology, Periodontal Ligament cytology
- Abstract
Periodontitis is a chronic-, infectious-disease of the human periodontium that is characterized by the loss of supporting tissues surrounding the tooth such as the periodontal ligament (PDL), cementum and alveolar bone. Regeneration of the periodontium is dependent on the participation of mesenchymal stem/stromal cells (MSC) resident in the PDL. Enamel matrix derivative (EMD), an extract from immature porcine enamel rich in amelogenin protein but that also contain bone morphogenetic protein (BMP), is used to treat periodontal defects. The effects of EMD on MSC cells of the PDL are not well characterized. In this in vitro study, we identify PDL progenitor cells from multiple individuals and demonstrate that EMD stimulates them. We show that the effect of EMD on cell proliferation and migration is mediated through the amelogenin it contains, while the differentiation of these progenitor cells to cell types of mineralized tissue is mainly due to BMP signaling., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
162. Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass.
- Author
-
Gennero I, Laurencin-Dalicieux S, Conte-Auriol F, Briand-Mésange F, Laurencin D, Rue J, Beton N, Malet N, Mus M, Tokumura A, Bourin P, Vico L, Brunel G, Oreffo RO, Chun J, and Salles JP
- Subjects
- Animals, Biomarkers metabolism, Bone Density, Bone Marrow Cells cytology, Bone Marrow Cells physiology, Bone and Bones anatomy & histology, Bone and Bones diagnostic imaging, Lysophospholipids metabolism, Mesenchymal Stem Cells cytology, Mesenchymal Stem Cells physiology, Mice, Mice, Inbred C57BL, Mice, Knockout, Nutritional Status, Osteoblasts cytology, Osteoblasts physiology, Osteoclasts cytology, Osteoclasts physiology, Protein Isoforms genetics, Receptors, Lysophosphatidic Acid genetics, X-Ray Microtomography, Bone and Bones abnormalities, Bone and Bones physiology, Cell Differentiation physiology, Osteogenesis physiology, Protein Isoforms metabolism, Receptors, Lysophosphatidic Acid metabolism
- Abstract
Lysophosphatidic acid (LPA) is a lipid mediator that acts in paracrine systems via interaction with a subset of G protein-coupled receptors (GPCRs). LPA promotes cell growth and differentiation, and has been shown to be implicated in a variety of developmental and pathophysiological processes. At least 6 LPA GPCRs have been identified to date: LPA1-LPA6. Several studies have suggested that local production of LPA by tissues and cells contributes to paracrine regulation, and a complex interplay between LPA and its receptors, LPA1 and LPA4, is believed to be involved in the regulation of bone cell activity. In particular, LPA1 may activate both osteoblasts and osteoclasts. However, its role has not as yet been examined with regard to the overall status of bone in vivo. We attempted to clarify this role by defining the bone phenotype of LPA1((-/-)) mice. These mice demonstrated significant bone defects and low bone mass, indicating that LPA1 plays an important role in osteogenesis. The LPA1((-/-)) mice also presented growth and sternal and costal abnormalities, which highlights the specific roles of LPA1 during bone development. Microcomputed tomography and histological analysis demonstrated osteoporosis in the trabecular and cortical bone of LPA1((-/-)) mice. Finally, bone marrow mesenchymal progenitors from these mice displayed decreased osteoblastic differentiation. These results suggest that LPA1 strongly influences bone development both qualitatively and quantitatively and that, in vivo, its absence results in decreased osteogenesis with no clear modification of osteoclasis. They open perspectives for a better understanding of the role of the LPA/LPA1 paracrine pathway in bone pathophysiology., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
163. Hypophosphatasia may lead to bone fragility: don't miss it.
- Author
-
Moulin P, Vaysse F, Bieth E, Mornet E, Gennero I, Dalicieux-Laurencin S, Baunin C, Tauber MT, De Gauzy JS, and Salles JP
- Subjects
- Adult, Child, Diagnosis, Differential, Exons, Female, Fractures, Spontaneous genetics, Humans, Hypophosphatasia blood, Hypophosphatasia genetics, Mothers, Pedigree, Siblings, Alkaline Phosphatase blood, Alkaline Phosphatase genetics, Fractures, Spontaneous etiology, Hypophosphatasia complications, Hypophosphatasia diagnosis, Mutation
- Abstract
Hypophosphatasia is an inheritable disorder characterised by defective bone mineralisation due to the impaired activity of tissue-non-specific alkaline phosphatase (AP). Clinical presentation ranges from stillbirth without mineralised bone to pathological fractures in late adulthood. During childhood, the main manifestations include rickets, growth delay and dental problems. Fractures and bone pain usually characterise the adult form. A 9-year-old girl was referred for repetitive fractures after minimal trauma. She had normal growth, normal sclerae, no rickets and minimal dental abnormalities. Her sister had also presented fractures. The proband, her sister and mother had low total and bone-specific AP levels and E435K mutation in exon 12 of the liver/bone/kidney AP gene. Low AP levels must lead to genetic analysis. Bone fragility and repetitive fractures may be symptoms of hypophosphatasia in childhood, which must not be neglected. Associated factors such as vitamin D or calcium deficiency must be prevented. In conclusion, hypophosphatasia must not be forgotten as an aetiological factor of repetitive fractures or bone pain in children and AP activity should be checked accurately.
- Published
- 2009
- Full Text
- View/download PDF
164. Detection of the A189G mtDNA heteroplasmic mutation in relation to age in modern and ancient bones.
- Author
-
Lacan M, Thèves C, Amory S, Keyser C, Crubézy E, Salles JP, Ludes B, and Telmon N
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Aging, Blotting, Southern, Female, Humans, Infant, Male, Middle Aged, Muscle, Skeletal pathology, Polymerase Chain Reaction, Sequence Analysis, DNA methods, DNA, Mitochondrial genetics, Point Mutation, Ribs pathology
- Abstract
The aim of this study was to demonstrate the presence of the A189G age-related point mutation on DNA extracted from bone. For this, a peptide nucleic acid (PNA)/DNA sequencing method which can determine an age threshold for the appearance of the mutation was used. Initially, work was done in muscle tissue in order to evaluate the sensitivity of the technique and afterwards in bone samples from the same individuals. This method was also applied to ancient bones from six well-preserved skeletal remains. The mutation was invariably found in muscle, and at a rate of up to 20% in individuals over 60 years old. In modern bones, the mutation was detected in individuals aged 38 years old or more, at a rate of up to 1%, but its occurrence was not systematic (only four out of ten of the individuals over 50 years old carried the heteroplasmy). For ancient bones, the mutation was also found in the oldest individuals according to osteologic markers. The study of this type of age-related mutation and a more complete understanding of its manifestation has potentially useful applications. Combined with traditional age markers, it could improve identification accuracy in forensic cases or in anthropological studies of ancient populations.
- Published
- 2009
- Full Text
- View/download PDF
165. Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes.
- Author
-
Fougerat A, Gayral S, Gourdy P, Schambourg A, Rückle T, Schwarz MK, Rommel C, Hirsch E, Arnal JF, Salles JP, Perret B, Breton-Douillon M, Wymann MP, and Laffargue M
- Subjects
- Animals, Apolipoproteins E deficiency, Apolipoproteins E genetics, Class Ib Phosphatidylinositol 3-Kinase, Disease Models, Animal, Humans, Inflammation drug therapy, Intramolecular Oxidoreductases deficiency, Intramolecular Oxidoreductases genetics, Isoenzymes antagonists & inhibitors, Mice, Mice, Inbred C57BL, Mice, Knockout, Prostaglandin-E Synthases, Receptors, LDL deficiency, Receptors, LDL genetics, Atherosclerosis drug therapy, Phosphoinositide-3 Kinase Inhibitors, Quinoxalines therapeutic use, Thiazolidinediones therapeutic use
- Abstract
Background: The role of inflammation at all stages of the atherosclerotic process has become an active area of investigation, and there is a notable quest for novel and innovative drugs for the treatment of atherosclerosis. The lipid kinase phosphoinositide 3-kinase-gamma (PI3Kgamma) is thought to be a key player in various inflammatory, autoimmune, and allergic processes. These properties and the expression of PI3Kgamma in the cardiovascular system suggest that PI3Kgamma plays a role in atherosclerosis., Methods and Results: Here, we demonstrate that a specific PI3Kgamma inhibitor (AS605240) is effective in murine models of established atherosclerosis. Intraperitoneal administration of AS605240 (10 mg/kg daily) significantly decreased early atherosclerotic lesions in apolipoprotein E-deficient mice and attenuated advanced atherosclerosis in low-density lipoprotein receptor-deficient mice. Furthermore, PI3Kgamma levels were elevated in both human and murine atherosclerotic lesions. Comparison of low-density lipoprotein receptor-deficient mice transplanted with wild-type or PI3Kgamma-deficient bone marrow demonstrated that functional PI3Kgamma in the hematopoietic lineage is required for atherosclerotic progression. Alleviation of atherosclerosis by targeting of PI3Kgamma activity was accompanied by decreased macrophage and T-cell infiltration, as well as increased plaque stabilization., Conclusions: These data identify PI3Kgamma as a new target in atherosclerosis with the potential to modulate multiple stages of atherosclerotic lesion formation, such as fatty streak constitution, cellular composition, and final fibrous cap establishment.
- Published
- 2008
- Full Text
- View/download PDF
166. Synthesis of new covalently bound kappa-carrageenan-AZT conjugates with improved anti-HIV activities.
- Author
-
Vlieghe P, Clerc T, Pannecouque C, Witvrouw M, De Clercq E, Salles JP, and Kraus JL
- Subjects
- Anti-HIV Agents pharmacology, Carbohydrate Sequence, Carrageenan chemical synthesis, Cells, Cultured, Drug Synergism, Humans, Molecular Sequence Data, Prodrugs pharmacology, Zidovudine chemical synthesis, Anti-HIV Agents chemical synthesis, Carrageenan chemistry, HIV-1 drug effects, Prodrugs chemical synthesis, Zidovudine chemistry
- Abstract
This paper describes the first covalent synthesis of kappa-carrageenan-3'-azido-3'-deoxythymidine (AZT) conjugates. A succinate diester spacer was used to covalently couple AZT onto kappa-carrageenan, resulting in a tripartite prodrug. Two methods (UV and radioactive counting) are described and validated to determine the AZT loading onto the kappa-carrageenan carrier. This polymeric carrier, through its own intrinsic anti-HIV activity, is expected to act not only as a drug delivery agent but also as an anti-HIV agent. Synergism between the two drugs (kappa-carrageenan and AZT) was demonstrated when MT-4 cells were preincubated with the kappa-carrageenan-AZT conjugate prior to HIV-1-infection. A threshold of AZT loaded onto the kappa-carrageenan was required to achieve this synergistic effect. Such kappa-carrageenan-AZT conjugates could be of great therapeutic interest because these conjugates, which contain a low AZT concentration, present improved anti-HIV activities relative to free AZT. Moreover, kappa-carrageenan is a well-tolerated biopolymer, already used in the food industry.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.